This unexpected discovery on the DRD2 being a direct-binding target for ONC201, has also led to the design and launch of a clinical trial of ONC201 in pheochromocytomas, owing to high levels of DRD2 expression in this rare tumor type (trial identifier: NCT03034200). The gene discussed is DRD2; the disease is neoplasm.